[1] XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants［J］.Chinese Medical Journal,2022,135(5):584-590.
[2] KIRTANE K,ELMARIAH H,CHUNG CH,et al.Adoptive cellular therapy in solid tumor malignancies:review of the literature and challenges ahead［J］.Journal for Immunotherapy of Cancer,2021,9(7):e002723.
[3] TITOV A,ZMIEVSKAYA E,GANEEVA I,et al.Adoptive Immunotherapy beyond CAR T-Cells［J］.Cancers,2021,13(4):743.
[4] PAIJENS ST,VLEDDER A,BRUYN M DE,et al.Tumor-infiltrating lymphocytes in the immunotherapy era［J］.Cellular & Molecular Immunology,2021,18(4):842-859.
[5] WANG S,SUN J,CHEN K,et al.Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors［J］.BMC Medicine,2021,19(1):140.
[6] ROSENBERG SA,SPIESS P,LAFRENIERE R.A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes［J］.Science(New York),1986,233(4770):1318-1321.
[7] ROSENBERG SA,PACKARD BS,AEBERSOLD PM,et al.Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.A preliminary report［J］.The New England Journal of Medicine,1988,319(25):1676-1680.
[8] GATTINONI L,FINKELSTEIN SE,KLEBANOFF CA,et al.Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells［J］.The Journal of Experimental Medicine,2005,202(7):907-912.
[9] DUDLEY ME,YANG JC,SHERRY R,et al.Adoptive cell therapy for patients with metastatic melanoma:evaluation of intensive myeloablative chemoradiation preparative regimens［J］.Journal of Clinical Oncology,2008,26(32):5233-5239.
[10] ROSENBERG SA,YANG JC,SHERRY RM,et al.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy［J］.Clinical Cancer Research,2011,17(13):4550-4557.
[11] DANAHER P,WARREN S,DENNIS L,et al.Gene expression markers of tumor infiltrating leukocytes［J］.Journal for Immunotherapy of Cancer,2017,5:18.
[12] SALGADO R,DENKERT C,DEMARIA S,et al.The evaluation of tumor-infiltrating lymphocytes(TILs)in breast cancer:recommendations by an International TILs Working Group 2014［J］.Annals of Oncology,2015,26(2):259-271.
[13] SALTZ J,GUPTA R,LE HOU,et al.Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images［J］.Cell Reports,2018,23(1):181-193.e7.
[14] FISHER B,PACKARD BS,READ EJ,et al.Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma［J］.Journal of Clinical Oncology,1989,7(2):250-261.
[15] GRIFFITH KD,READ EJ,CARRASQUILLO JA,et al.In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma［J］.Journal of the National Cancer Institute,1989,81(22):1709-1717.
[16]］ PITTET MJ,GRIMM J,BERGER CR,et al.In vivo imaging of T cell delivery to tumors after adoptive transfer therapy［J］.Proceedings of the National Academy of Sciences of the United States of America,2007,104(30):12457-12461.
[17] ZHAO H,WANG C,YANG Y,et al.ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents［J］.Journal of Nanobiotechnology,2021,19(1):42.
[18] FARWELL MD,GAMACHE RF,BABAZADA H,et al.CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer:A phase I first-in-humans study of 89Zr-Df-IAB22M2C,a radiolabeled anti-CD8 minibody［J］.Journal of Nuclear Medicine,2022,63(5):720-726.
[19] HONG JJ,ROSENBERG SA,DUDLEY ME,et al.Successful treatment of melanoma brain metastases with adoptive cell therapy［J］.Clinical Cancer Research,2010,16(19):4892-4898.
[20] CHANDRAN SS,SOMERVILLE RPT,YANG JC,et al.Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes:a single-centre,two-stage,single-arm,phase 2 study［J］.The Lancet Oncology,2017,18(6):792-802.
[21] DAFNI U,MICHIELIN O,LLUESMA SM,et al.Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma:a systematic review and meta-analysis［J］.Annals of Oncology,2019,30(12):1902-1913.
[22] SARNAIK AA,HAMID O,KHUSHALANI NI,et al.Lifileucel,a tumor-infiltrating lymphocyte therapy,in metastatic melanoma［J］.Journal of Clinical Oncology,2021,39(24):2656-2666.
[23] RATTO GB,ZINO P,MIRABELLI S,et al.A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer［J］.Cancer,1996,78(2):244-251.
[24] RATTO GB,MELIOLI G,ZINO P,et al.Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer:A pilot study［J］.The Journal of Thoracic and Cardiovascular Surgery,1995,109(6):1212-1217.
[25] CREELAN BC,WANG C,TEER JK,et al.Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer:a phase 1 trial［J］.Nature Medicine,2021,27(8):1410-1418.
[26] LEE SM,HAIGENTZ M,VILLARUZ LC,et al.A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes(TIL,LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC［J］.Journal of Clinical Oncology,2018,36(15_suppl):TPS3107.
[27] STEVANOVIC S,DRAPER LM,LANGHAN MM,et al.Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells［J］.Journal of Clinical Oncology,2015,33(14):1543-1550.
[28] STEVANOVIC S,HELMAN SR,WUNDERLICH JR,et al.A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers［J］.Clinical Cancer Research,2019,25(5):1486-1493.
[29] HUANG H,NIE CP,LIU XF,et al.Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer［J］.The Journal of Clinical Investigation,2022,132(15):e157726.
[30] GUO J,LUO N,AI G,et al.Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen［J］.Journal for Immunotherapy of Cancer,2022,10(2):e003887.
[31] JAZAERI AA,ZSIROS E,AMARIA RN,et al.Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes(LN-145) for treatment of recurrent,metastatic,or persistent cervical carcinoma［J］.Journal of Clinical Oncology,2019,37(15_suppl):2538.
[32] ZACHARAKIS N,CHINNASAMY H,BLACK M,et al.Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer［J］.Nature Medicine,2018,24(6):724-730.
[33] ZACHARAKIS N,HUQ LM,SEITTER SJ,et al.Breast cancers are immunogenic:Immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes［J］.Journal of Clinical Oncology,2022,40(16):1741-1754.
[34] SONG H,WANG H,GONG M,et al.Augmentation of antitumor function of tumor-infiltrating lymphocytes against triple-negative breast cancer by PD-1 blockade［J］.Cell Biology International,2022,46(2):278-287.
[35] AOKI Y,TAKAKUWA K,KODAMA S,et al.Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer［J］.Cancer Research,1991,51(7):1934-1939.
[36] FREEDMAN RS,EDWARDS CL,KAVANAGH JJ,et al.Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2:a pilot trial［J］.Journal of Immunotherapy with Emphasis on Tumor Immunology,1994,16(3):198-210.
[37] PEDERSEN M,WESTERGAARD MCW,MILNE K,et al.Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer:a pilot study［J］.Oncoimmunology,2018,7(12):e1502905.
[38] LI J,CHEN QY,HE J,et al.Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma［J］.Oncoimmunology,2015,4(2):e976507.
[39] SHI J,LI M,YANG R.Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy［J］.Immunotherapy,2020,12(9):641-652.
[40] LEIDNER RS,SUKARI A,CHUNG CH,et al.A phase 2,multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes(LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck(HNSCC)［J］.Journal of Clinical Oncology,2018,36(15_suppl):TPS6096.
[41] POCH M,HALL M,JOERGER A,et al.Expansion of tumor infiltrating lymphocytes(TIL)from bladder cancer［J］.Oncoimmunology,2018,7(9):e1476816.
[42] BRAUN MW,ABDELHAKIM H,LI M,et al.Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer［J］.Journal for Immunotherapy of Cancer,2020,8(2):e000706.
[43] AYDIN AM,HALL M,BUNCH BL,et al.Expansion of tumor-infiltrating lymphocytes(TIL) from penile cancer patients［J］.International Immunopharmacology,2021,94:107481.
[44] KO A,COWARD VS,GOKGOZ N,et al.Investigating the potential of isolating and expanding tumour-infiltrating lymphocytes from adult sarcoma［J］.Cancers,2022,14(3):548.
[45] LIU Z,MENG Q,BARTEK J,et al.Tumor-infiltrating lymphocytes(TILs)from patients with glioma［J］.Oncoimmunology,2017,6(2):e1252894.
[46] MENG Q,LIU Z,RANGELOVA E,et al.Expansion of tumor-reactive T cells from patients with pancreatic cancer［J］.Journal of Immunotherapy(Hagerstown,Md.1997),2016,39(2):81-89.
[47] HUSE M.The T-cell-receptor signaling network［J］.Journal of Cell Science,2009,122(Pt 9):1269-1273.
[48] POL JG,CAUDANA P,PAILLET J,et al.Effects of interleukin-2 in immunostimulation and immunosuppression［J］.The Journal of Experimental Medicine,2020,217(1):e20191247.
[49] KVERNELAND AH,CHAMBERLAIN CA,BORCH TH,et al.Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types［J］.Journal for Immunotherapy of Cancer,2021,9(10):e003499.
[50] RADVANYI LG,BERNATCHEZ C,ZHANG M,et al.Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients［J］.Clinical Cancer Research,2012,18(24):6758-6770.
[51] ZHOU J,SHEN X,HUANG J,et al.Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy［J］.Journal of Immunology(Baltimore,Md.1950),2005,175(10):7046-7052.
[52] KRISTENSEN NP,HEEKE C,TVINGSHOLM SA,et al.Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma［J］.The Journal of Clinical Investigation,2022,132(2):e150535.
[53] KIM SP,VALE NR,ZACHARAKIS N,et al.Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors［J］.Cancer Immunology Research,2022,10(8):932-946.
[54] CHU J,WANG C,MA Q,et al.Coupling programmed cell death 1-positive tumor-infiltrating T cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy［J］.Cytotherapy,2022,24(3):291-301.
[55] PARKHURST M,GROS A,PASETTO A,et al.Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression［J］.Clinical Cancer Research,2017,23(10):2491-2505.
[56] DUHEN R,BALLESTEROS-MERINO C,FRYE A K,et al.Neoadjuvant anti-OX40(MEDI6469)therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells［J］.Nature Communications,2021,12(1):1047.
[57] KRISHNA S,LOWERY FJ,COPELAND AR,et al.Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer［J］.Science(New York),2020,370(6522):1328-1334.
[58] DIAZ-CANO I,PAZ-ARES L,OTANO I.Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy［J］.International Review of Cell and Molecular Biology,2022,370:163-192.
[59] FREEMAN P,MIELGO A.Cancer-associated fibroblast mediated inhibition of CD8+ cytotoxic T cell accumulation in tumours:Mechanisms and therapeutic opportunities［J］.Cancers,2020,12(9):2687.
[60] LI X,XIANG Y,LI F,et al.WNT/β-Catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment［J］.Frontiers in Immunology,2019,10:2293.
[61] GALLUZZI L,SPRANGER S,FUCHS E,et al.WNT signaling in cancer immunosurveillance［J］.Trends in Cell Biology,2019,29(1):44-65.
[62] XIA L,OYANG L,LIN J,et al.The cancer metabolic reprogramming and immune response［J］.Molecular Cancer,2021,20(1):28.
[63] WANG Y,WANG C,HUANG M,et al.Pilot study of a novel nanobody 68 Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells［J］.European Journal of Nuclear Medicine and Molecular Imaging,2022,49(13):4394-4405.
[64] SEITTER SJ,SHERRY RM,YANG JC,et al.Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma［J］.Clinical Cancer Research,2021,27(19):5289-5298.
[65] FORGET MA,HAYMAKER C,HESS KR,et al.Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma:Response,impact of anti-CTLA4,and biomarkers to predict clinical outcome［J］.Clinical Cancer Research,2018,24(18):4416-4428.
[66] SABERIAN C,AMARIA RN,NAJJAR AM,et al.Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes,with or without dendritic cell vaccination,in patients with metastatic melanoma［J］.Journal for Immunotherapy of Cancer,2021,9(5):e002449.
[67] BORCH TH,HARBST K,RANA AH,et al.Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma［J］.Journal for Immunotherapy of Cancer,2021,9(7):e002703.
[68] ZHANG J,ENDRES S,KOBOLD S.Enhancing tumor T cell infiltration to enable cancer immunotherapy［J］.Immunotherapy,2019,11(3):201-213.
[69] BINNEWIES M,POLLACK JL,RUDOLPH J,et al.Targeting TREM2 on tumor-associated macrophages enhances immunotherapy［J］.Cell Reports,2021,37(3):109844.
[70] WANG Y,WANG C,QIU J,et al.Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer［J］.Journal for Immunotherapy of Cancer,2022,10(3):e003667.
[71] WU J,CHEN Z,WICKSTRM SL,et al.Interleukin-33 is a novel immunosuppressor that protects cancer cells from TIL killing by a macrophage-mediated shedding mechanism［J］.Advanced Science(Weinheim,Baden-Wurttemberg,Germany),2021,8(21):e2101029.
[72] CHAMBERLAIN CA,BENNETT EP,KVERNELAND AH,et al.Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy［J］.Molecular Therapy Oncolytics,2022,24:417-428.